Pharmaceutical company in
Muttenz

Acta Klinika GmbH

Since 2021 · 1–10 empl.·5.0(58)

Acta Klinika GmbH is a life-science company that develops and sells natural dietary supplements. The company states it conducts research and development with partners including developers and universities and has its products manufactured by a Swiss contract manufacturer according to cGMP standards; an example product is the XNS capsule (black seed oil with vitamin E), sold via the webshop and pharmacies.

Dr. Wild & Co. AG

Since 2007 · 51–100 empl.·4.5(12)

Dr. Wild & Co. AG develops and sells oral care products including toothpastes, gels, mouthwashes and related dental care items. The company markets several product lines (e.g. EMOFORM, TEBODONT, DEPURDENT) and manufactures many of its products in Switzerland.

Medius AG

Since 1997 · 1–10 empl.

The core activity of Medius AG is to provide services in the field of regulatory affairs for pharmaceuticals and health products, including market authorization, quality assurance and development. The company particularly supports international companies in their market entry into Switzerland and offers consulting and services in these areas.

Opterion Health AG

Since 2012 · 11–20 empl.

The core activity of Opterion Health AG is the development and marketing of a new, non-glucose-based osmotic agent for peritoneal dialysis (PD) in patients with end-stage renal disease. The company focuses on creating an innovative product that reduces the metabolic side effects of conventional glucose-based solutions and improves the quality of life for patients.

INOFEA AG

Since 2014 · 11–20 empl.

INOFEA AG develops biotechnology-based enzyme solutions for manufacturing biologics, including mRNA and antibody-drug conjugates, and pharmaceutical active ingredients. Its patented technology immobilizes and shields enzymes to improve their stability and enable their use in continuous or flow-through processes.

Primopus AG

Since 2020 · 1–10 empl.

The core activity of Primopus AG is the development and manufacture of pharmaceutical active ingredients and intermediates as a Contract Development and Manufacturing Organization (CDMO). They offer services such as process development, manufacturing and backward integration of pharmaceutical active ingredients, including the production of phosphoramidites and Fmoc amino acids.

Perseo pharma AG

Since 2019 · 11–20 empl.

Perseo pharma AG is a preclinical biopharmaceutical company developing oral enzyme therapies for digestive diseases. Its nanotechnology platform protects enzymes and binds them to the small-intestinal mucosa; the company is also researching applications in other metabolic therapies.

DYALENT Science&Technology GmbH

Since 2023 · 1–10 empl.

Dyalent provides laboratory analyses and services to various industries, including pharmaceuticals, cosmetics, food and consumer goods. The company's core activity encompasses conducting laboratory analyses, developing and marketing laboratory products and equipment, as well as providing laboratory automation solutions. Dyalent also offers comprehensive support to customers, including consulting, logistics and administration, to ensure that products are safe, compliant with regulations and of the highest quality.

Corden Pharma Schweizerhalle GmbH

Since 2025 · 1–10 empl.

Corden Pharma Schweizerhalle GmbH is a pharmaceutical company that provides CDMO services for the development and manufacturing of active ingredients and drug products. Its capabilities include peptides, oligonucleotides, lipids and LNPs, injectables, and other complex dosage forms, supporting projects from development through commercial manufacturing.

Bloocell Suisse AG

Since 2025 · 1–10 empl.

Bloocell Suisse AG develops and distributes artificial tissue technologies in the field of tissue engineering. The company offers products and solutions for several medical applications, including orthopedics, dentistry, ENT, neurosurgery, plastic and reconstructive surgery, thoracic surgery, and maxillofacial surgery.

Antares Pharma GmbH

Since 1997 · 1–10 empl.